GenSight Biologics Announces its 2021 Money Calendar | Business enterprise & Finance

GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME suitable), a biopharma organization targeted on developing and commercializing revolutionary gene therapies for retinal neurodegenerative conditions and central anxious technique diseases, today declared its monetary calendar for 2021.

* This economical calendar is furnished for facts only and might be topic to adjustments. The Company’s updated economic calendar is out there on its corporate internet site.

GenSight Biologics S.A. is a clinical-phase biopharma company centered on creating and commercializing ground breaking gene therapies for retinal neurodegenerative illnesses and central anxious program ailments. GenSight Biologics’ pipeline leverages two main technological innovation platforms, the Mitochondrial Focusing on Sequence (MTS) and optogenetics, to assist preserve or restore vision in sufferers suffering from blinding retinal diseases. Utilizing its gene remedy-primarily based approach, GenSight Biologics’ item candidates are built to be administered in a solitary treatment to each eye by intravitreal injection to offer sufferers a sustainable functional visual recovery. Designed as a remedy for Leber Hereditary Optic Neuropathy (LHON), GenSight Biologics’ direct product or service candidate, LUMEVOQ ® (GS010 lenadogene nolparvovec), is at the moment in the critique section of its registration approach in Europe, and in Period III to move ahead to a BLA filing in the U.S.

Speak to: GenSight Biologics

+33 ()1 76 21 72 20RooneyPartners

+1-646-537-5649LifeSci Advisors

+41 ()76 735 01 31Orpheon Finance

Search term: EUROPE UNITED STATES NORTH America FRANCE

Business Search phrase: Wellbeing GENETICS OTHER Overall health Basic Health Scientific TRIALS PHARMACEUTICAL BIOTECHNOLOGY

Source: GenSight Biologics

Copyright Small business Wire 2021.

PUB: 01/18/2021 11:58 AM/DISC: 01/18/2021 11:59 AM